SRZN
Surrozen, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Surrozen, Inc.
Expected move
No implied move.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Surrozen, Inc.
29.11
+0.09 · +0.32%
post 29.79 +2.33%
News
Bull2
Bear2
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| TCG Crossover | $38.2M | 14.23% | 0.00% |
| Boxer | $27.0M | 10.04% | +44.29% |
| Millennium | $17.7M | 6.60% | −6.57% |
| Point72 | $17.2M | 6.42% | new |
| VR Adviser | $16.4M | 6.12% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| TCG Crossover | $38.2M | 14.23% | 0.00% |
| Boxer | $27.0M | 10.04% | +44.29% |
| Millennium | $17.7M | 6.60% | −6.57% |
| Point72 | $17.2M | 6.42% | new |
| VR Adviser | $16.4M | 6.12% | 0.00% |
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Surrozen, Inc..
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Surrozen, Inc..
Annual filing, covered
10-K parsed · Mar 23 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 23 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.